PHASE-II TRIAL OF N-METHYLFORMAMIDE IN PATIENTS WITH METASTATIC MELANOMA

被引:0
作者
ETON, O
BAJORIN, DF
CASPER, ES
HOUGHTON, AN
机构
[1] MEM SLOAN KETTERING CANC CTR,DIV SOLID TUMOR ONCOL,1275 YORK AVE,NEW YORK,NY 10021
[2] MEM SLOAN KETTERING CANC CTR,DEPT MED,CLIN IMMUNOL SERV,NEW YORK,NY 10021
[3] CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021
关键词
N-METHYLFORMAMIDE; MELANOMA; CHEMOTHERAPY; PHASE-II;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sixteen patients with metastatic melanoma were treated with N-methylformamide (NMF), a polar-planar compound with in vitro cytotoxic and differentiating properties. Sixteen patients were evauable for toxicity and 14 for response. The initial four patients received an intravenous bolus of NMF 800 mg/m2 daily for 5 consecutive days every 28 days. Because of excessive gastrointestinal toxicity, the dose was reduced to 700 mg/m2/day for the subsequent 12 patients. Two patients had immediate adverse effects from NMF; one had a grand mal seizure and the other developed severe abdominal pain. Nausea, vomiting and abdominal pain were dose-limiting. Transient elevation of liver function tests occurred in all patients. Myelosuppression was not observed. There were no objective responses among 14 evaluable patients (95% confidence limits 0-20%). One patient with pulmonary metastases had a minor response lasting 13 months. Median time to progression of disease was one month. NMF in these doses and schedule lacks clinical efficacy in the treatment of metastatic melanoma.
引用
收藏
页码:97 / 100
页数:4
相关论文
共 10 条
[1]   N-METHYLFORMAMIDE - CYTO-TOXIC, RADIOSENSITIZER, OR CHEMOSENSITIZER [J].
CLAGETTCARR, K ;
SAROSY, G ;
PLOWMAN, J ;
HOTH, DF ;
LEYLANDJONES, B .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (05) :906-918
[2]  
DEXTER DL, 1982, CLIN RES, V30, pA532
[3]  
EISENHAUER EA, 1986, CANCER TREAT REP, V70, P881
[4]  
MCVIE JG, 1984, CANCER TREAT REP, V68, P607
[5]  
MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[6]  
2-6
[7]   CLINICAL-PHARMACOLOGY OF ORAL AND IV N-METHYLFORMAMIDE - A PHARMACOLOGIC BASIS FOR LACK OF CLINICAL ANTINEOPLASTIC ACTIVITY [J].
ROWINSKY, EK ;
NOE, DA ;
ORR, DW ;
GROCHOW, LB ;
ETTINGER, DS ;
DONEHOWER, RC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (09) :671-678
[8]  
SCHLAM ML, 1984, P AM ASSOC CANC RES, V25, P39
[9]  
STERNBERG CN, 1986, CANCER TREAT REP, V70, P681
[10]  
YOUNG CW, 1988, CANCER RES, V48, P7304